BASF, Poietis sign agreement 3D bioprinting technology

BASF, Poietis sign agreement on 3D bioprinting technology

10:55 AM, 30th October 2017
BASF, Poietis sign agreement on 3D bioprinting technology

LUDWIGSHAFEN, GERMANY / PESSAC, FRANCE: BASF SE and Poietis SAS have signed a framework agreement on further development and services in the field of 3D bioprinting technology. The main goal is to further improve the 3D laser-assisted bioprinted skin models that have been co-developed since 2015 to evaluate cosmetic ingredients for skin care applications.

The 3D laser-assisted bioprinting technology, by which organic tissues can be reproduced, allows a precise positioning of skin cells in three-dimensional structures. Thus, it is now possible to produce fully printed skin equivalents in only two weeks to further study active ingredients effectiveness.

In the coming years, BASF intends to develop and market several active ingredients for cosmetic products that harness the findings of the collaboration. At this year's Cosmetagora, Dermagenist led the way being BASF’s first active ingredient whose efficacy has been confirmed by using laser-assisted bioprinted skin models.

“Bio-printed 3D models are the method of choice for the predictive evaluation of ingredients as these models reproduce the cell environment in vitro by having mechanical and metabolic functionalities close to the vivo,” said Fabien Guillemot, founder and president of Poietis.

“During our cooperation, we gained important insights like the parameters and kinetics of dermis maturation. A mature and thick dermis is an essential condition to obtain optimum results in epidermal printing,” said Sebastien Cadau, responsible for tissue engineering development at BASF.

“In a first step, the new technology has been used to allow an automated reproduction of BASF’s skin model Mimeskin, which is one of the closest equivalents to the original physiological tissue of human skin. In a second step, we now want to jointly improve the skin models by increasing structure complexity and adding new cell types,” added Cadau.

“This agreement confirms a fruitful scientific collaboration and strengthens our partnership with the leading ingredients manufacturer for the personal care market. This is a formal recognition of Poietis' unique technology and its valorization driven by new developments since the creation of the company,” said Bruno Brisson, Poietis co-founder and vice president business development.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Sika opens second concrete admixtures facility in Angola

BAAR, SWITZERLAND: Sika AG opens a new concrete admixtures facility in the Angolan capital, Luanda, expanding its presence in Africa. In addition to t ...

Read more
ExxonMobil to acquire 33 pc interest in Statoil’s Carcara oil field

IRVING, US: ExxonMobil Corporation has completed an agreement to purchase half of Statoil’s interest in the BM-S-8 block offshore Brazil, which ...

Read more
Brenntag holds key handover ceremony for new headquarters in Essen

ESSEN, GERMANY: Brenntag AG celebrates the official hand-over of the keys to its new company headquarters in Essen, Germany. Employees are scheduled t ...

Read more
Clariant expands mining solution support for Mexico

HOUSTON, US: Clariant International Ltd for the first time has expanded its comprehensive suite of mining-specific product innovations and technical e ...

Read more
New gene-editing tool that could eliminate hundreds of diseases

CAMBRIDGE, US: Scientists at Harvard University and the Broad Institute of MIT and Harvard have developed a new class of genome editing tool. This new ...

Read more
AkzoNobel confirms talks about potential merger with Axalta

AMSTERDAM, NETHERLANDS: AkzoNobel NV has confirmed that it is currently in constructive discussions regarding a merger of the AkzoNobel paints & c ...

Read more